Work

Next Steps in the CAR Journey of a Thousand Miles

Year: 2017

Type: article

Abstract: The US Food and Drug Administration’s (FDA’s) recent approval of Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia1 represents a triumph for the academic and pharmaceutical industry collaborators who enabled the success of this CD19 antigen-directed chimeric antigen receptor (CAR) T cell product. The stunning complete response rate in otherwise refractory disease has rightly attracted enormous attention and comment,2 which will not be added to here. Of almost equal importance, however, is that approval is focusing attention on the new resources and policies required if the success of CD19 CAR T cell treatment of B cell malignancies is to be more broadly replicated.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2017.09.013

Author: Malcolm K. Brenner

Institutions: Houston Methodist, Baylor College of Medicine, Texas Children's Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500